Effect of Fluvastatin on Lipids and Fibrinolysis in Coronary Artery Disease

This randomized, double-blind, placebo-controlled study shows that 20-week fluvastatin treatment induces beneficial changes in the lipid panel and a shift in the fibrinolytic pathway toward activation through a decrease in tissue plasminogen activator antigen. Fluvastatin treatment causes no variati...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The American journal of cardiology 1997-01, Vol.79 (1), p.84-87
Hauptverfasser:	Bevilacqua, Maurizio, Bettica, Paolo, Milani, Massimo, Vago, Tarcisio, Rogolino, Angela, Righini, Velella, Santoli, Edoardo, Norbiato, Guido
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Anticholesteremic Agents - pharmacology Apolipoproteins A - blood Apolipoproteins B - blood Biological and medical sciences Cardiovascular disease Cholesterol, HDL - blood Cholesterol, LDL - blood Coronary Disease - physiopathology Coronary vessels Double-Blind Method Drug therapy Enzyme Inhibitors - pharmacology Fatty Acids, Monounsaturated - pharmacology Female Fibrinolysis - drug effects Fluvastatin General and cellular metabolism. Vitamins Humans Hydroxymethylglutaryl CoA Reductases Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology Indoles - pharmacology Lipids Lipids - blood Male Medical sciences Middle Aged Pharmacology. Drug treatments Plasminogen Activator Inhibitor 1 - blood Triglycerides - blood
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	This randomized, double-blind, placebo-controlled study shows that 20-week fluvastatin treatment induces beneficial changes in the lipid panel and a shift in the fibrinolytic pathway toward activation through a decrease in tissue plasminogen activator antigen. Fluvastatin treatment causes no variation in lipoprotein(a) circulating levels.
ISSN:	0002-9149 1879-1913
DOI:	10.1016/S0002-9149(96)00684-4